Immunomedics reported clinical trial results Monday showing its newly approved medicine, Trodelvy, reduced the risk of tumor progression or death by 59% compared to chemotherapy in patients with an aggressive type of metastatic breast cancer.
Trodelvy also prolonged overall survival in the same patients, although the magnitude of the survival benefit is being withheld for now so the data can be presented at a later medical meeting, the company said.
Immunomedics secured accelerated approval for Trodelvy in April to treat women with triple-negative breast cancer. These are tumors that do not carry receptors for estrogen, progesterone, or human epidermal growth factor, typically targeted by such drugs as Herceptin or tamoxifen. It’s a more aggressive form of breast cancer that is harder to treat and with fewer approved medicines available.
About the Author Reprints
